Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | BCL2L11 | O43521 | 2/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | WNT1 | P04628 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12460160 | 0.85 | ALPI (0.47) | KDM4EALDH1A1HDAC3HDAC8NCOR2 | |
| SCHEMBL24883514 | 0.84 | KDM4E (0.43) | KDM4EALDH1A1HDAC3HDAC8NCOR2 | |
| SCHEMBL16553920 | 0.84 | ALDH1A1 (0.40) | KDM4EALDH1A1HDAC3HDAC8NCOR2 | |
| SCHEMBL25247129 | 0.84 | HSD17B10 (0.43) | KDM4EALDH1A1HDAC3HDAC8NCOR2 | |
| SCHEMBL13172593 | 0.84 | ALDH1A1 (0.40) | KDM4EALDH1A1HDAC3HDAC8NCOR2 | |
| SCHEMBL24269268 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1HDAC3HDAC8NCOR2 | |
| SCHEMBL24883759 | 0.83 | KDM4E (0.39) | KDM4EALDH1A1HDAC3HDAC8NCOR2 | |
| SCHEMBL13172345 | 0.83 | KDM4E (0.39) | KDM4EALDH1A1HDAC6 | |
| SCHEMBL13165384 | 0.83 | ALDH1A1 (0.39) | KDM4EALDH1A1HDAC3HDAC8NCOR2 | |
| SCHEMBL27806606 | 0.83 | L3MBTL1 (0.54) | KDM4EALDH1A1HDAC3HDAC8NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| US-20090036485-A1 | Quinoline derivatives | JUNG FREDERIC HENRI | 2009-02-05 | — | — | US | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802603-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040522-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036485-A1 | Quinoline derivatives | AQP3, PGF, AQP1 | KDM4E 2931/4885ALDH1A1 1431/4885HDAC3 627/4885 |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | KDM4E 2349/4885ALDH1A1 2449/4885HDAC3 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.